Please try another search
Psyence Biomedical Ltd. engages in the development of natural psilocybin products for the healing of psychological trauma and mental health consequences in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial using PEX010, a 25mg naturally derived psilocybin drug candidate product for the palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Name | Age | Since | Title |
---|---|---|---|
Christopher Michael Bull | 55 | 2024 | Independent Director |
Marc Gregory Balkin | 50 | 2024 | Independent Director |
Neil Maresky | 59 | 2023 | CEO & Director |
Jody Aufrichtig | 50 | 2024 | Co-Founder, Executive Chairman & Strategic Business Development Officer |
Seth Feuerstein | 51 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review